ARTICLE SUMMARY:
Sequel Med Tech began a limited US launch of its new twiist automated insulin delivery system in July and is working toward full launch by year’s end. In this brief Q&A, Chris Gilbert, Sequel’s VP of marketing, provides more details on the company’s competitive strategy and its future plans.
Medtronic’s pending spin-off of its diabetes device business is sure to shake up the diabetes competitive landscape in the future, but new entrants could also have a large role to play in the months and years ahead. (See “In the Ever-Shifting Diabetes Device Market, Flexibility and Focus Are Key,” MedTech Strategist, June 25, 2025.)
The newest competitor in the US automated insulin delivery (AID) market is Sequel Med Tech, which began a limited US launch of its twiist AID system in July. The company is entering a very competitive space but hopes to differentiate itself by offering an AID system that gives users “more control, flexibility, and personalization.”
